ArticleVaccine: X2024

A phase 3, randomised, observer-blinded, placebo controlled-trial evaluating the safety and immunogenicity of investigational SARS-CoV-2 mRNA vaccine CVnCoV in adult healthcare workers in Mainz (Germany).

Frank Kowalzik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.